Table 1.
Baseline patient demographics and tumour characteristics
| Characteristic | Number of patients (n = 27) (%) | |
|---|---|---|
| Age at diagnosis (years) | <50 | 19 (70) |
| ≥50 | 8 (30) | |
| Menopausal status | Pre-menopausal | 19 (70) |
| Post-menopausal | 6 (22) | |
| Perimenopausal | 1 (4) | |
| Unevaluable | 1 (4) | |
| Histological characteristic | Invasive ductal carcinoma | 21 (78) |
| Invasive lobular carcinoma | 4 (15) | |
| Other or not otherwise specified | 2 (7) | |
| Grade | I | 2 (7) |
| II | 13 (48) | |
| III | 11 (41) | |
| Unknown or unevaluable | 1 (4) | |
| Clinical tumour stage | T2 | 13 (48) |
| T3 | 11 (41) | |
| T4 | 3 (11) | |
| Clinical nodal stage | Positive | 15 (56) |
| Negative | 12 (44) | |
| Oestrogen receptor status | Positive | 15 (56) |
| Negative | 12 (44) | |
| Progesterone receptor status | Positive | 12 (44) |
| Negative | 13 (48) | |
| Unknown or unevaluable | 2 (8) | |
| Human epidermal growth factor receptor 2 (HER2) status | Positive | 6 (22) |
| Negative | 20 (74) | |
| Unknown or unevaluable | 1 (4) | |